Esperion Hits JPM Stage on Heels of Strong Sales and Key Drug Wins

ANN ARBOR, MI – January 05, 2026 – Esperion Therapeutics is set to take the stage at the prestigious 44th Annual J.P. Morgan Healthcare Conference, a key event where the biopharmaceutical company will detail its growth strategy to a critical audience of investors and industry leaders. The presentation, scheduled for January 14, 2025, comes at a pivotal moment for the company, which has been buoyed by soaring revenues for its non-statin cholesterol therapies and significant endorsements from major medical bodies.

As announced, company leadership will present and participate in a fireside chat, an opportunity to build on recent momentum and articulate its vision for the future. For Esperion, the conference is more than a routine update; it's a platform to cement its position as a key player in cardiovascular health and showcase a burgeoning pipeline that extends far beyond its current commercial successes.

Riding a Wave of Commercial Success

Esperion heads to the conference backed by a period of exceptional financial performance. The company’s most recent earnings reports from late 2024 paint a picture of a company hitting its commercial stride. In the fourth quarter of 2024, Esperion reported total revenues of $69.1 million, a staggering 114% increase year-over-year that comfortably beat analyst expectations. For the full year, total revenue skyrocketed 186% to $332.3 million.

This explosive growth was driven by the robust performance of its U.S. products, NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). U.S. net product revenue climbed 52% year-over-year in the fourth quarter, fueled by a 45% increase in retail prescription volumes. This surge followed the U.S. Food and Drug Administration's decision in March 2024 to significantly broaden the drugs' labels to include cardiovascular risk reduction and treatment for primary hyperlipidemia, with or without statin therapy. This expansion opened the door to a much larger patient population.

Financially, the company has also demonstrated increasing discipline. Its net loss narrowed significantly, and its adjusted loss per share of $0.11 in Q4 2024 was better than Wall Street had forecast. With a healthy cash position of $144.8 million at the end of 2024 and expanded insurance coverage reaching over 165 million patient lives, Esperion is signaling to investors that it is on a clear trajectory toward profitability.

Beyond Statins: Carving a Niche in Cardiovascular Health

The commercial success of NEXLETOL and NEXLIZET is rooted in their unique position within the competitive landscape of LDL-cholesterol (LDL-C) lowering therapies. As oral, once-daily, non-statin treatments, they offer a vital alternative for a substantial patient population: those who are intolerant to statins or who require additional LDL-C reduction on top of maximally tolerated statin therapy.

Unlike injectable competitors such as PCSK9 inhibitors, Esperion’s pills offer convenience, a key factor in patient adherence. The therapy works by inhibiting ATP Citrate Lyase (ACLY), an enzyme upstream of the enzyme targeted by statins in the liver's cholesterol synthesis pathway. This mechanism of action has proven effective, but the game-changer for Esperion was the data from its landmark CLEAR Cardiovascular Outcomes Trial.

The nearly 14,000-patient study demonstrated that bempedoic acid not only lowers LDL-C but also significantly reduces the risk of major adverse cardiovascular events. This outcomes data elevated the therapy from simply a cholesterol-lowering agent to a proven tool for cardiovascular risk reduction, a critical distinction for physicians and payers.

This clinical validation has been followed by powerful endorsements from medical guideline committees. In August 2025, the influential European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) granted bempedoic acid a top-tier Level 1a recommendation. The guidelines positioned it as the only newly recommended non-statin oral therapy for both statin-intolerant patients and as an add-on for high-risk patients failing to meet cholesterol goals. This was followed in December 2025 by a recommendation in the American College of Cardiology (ACC) scientific statement for managing peripheral artery disease, further cementing its role in clinical practice.

The J.P. Morgan Spotlight and Investor Expectations

Against this backdrop of clinical and commercial wins, Esperion's presentation at the J.P. Morgan conference is highly anticipated. The conference is a premier venue for dealmaking and strategic announcements, and investors will be listening intently for signals about the company's next phase of growth.

Key among investor expectations is a detailed roadmap to sustained profitability. While revenue growth has been impressive, the focus now shifts to translating that top-line success into bottom-line results. Analysts will be scrutinizing operating expense guidance and the company’s strategy for leveraging its existing commercial infrastructure to maximize efficiency.

"A company at this stage needs to prove its commercial model is not only effective but sustainable," commented one biopharma industry analyst. "Investors will be looking for a clear narrative that connects recent commercial wins to a durable, profitable future, especially as the market for cardiovascular therapies evolves."

Furthermore, the presentation will be a key opportunity to discuss strategic partnerships. The recent agreement with CSL Seqirus to commercialize its therapies in Australia and New Zealand is a template for future international expansion. Updates on plans for other major markets, such as Japan, will be closely watched as indicators of the company's global ambitions.

Building the Future on ACLY Biology

While its cholesterol franchise is the current engine of growth, Esperion is keen to show investors that its future is not limited to cardiovascular disease. The company is heavily invested in leveraging its deep expertise in ACLY biology to build a diversified pipeline of novel therapies.

At a recent R&D day, Esperion unveiled its next-generation ACLY inhibition program, which is exploring more potent and selective drug candidates. This includes the development of allosteric inhibitors, a novel approach that could lead to highly differentiated new chemical entities. The company has identified its lead indication for this next-generation program: Primary Sclerosing Cholangitis (PSC), a rare and serious chronic liver disease with no approved treatments.

By targeting the underlying mechanisms of bile duct injury and fibrosis, Esperion believes its ACLY platform has transformative potential in PSC and other rare conditions, including certain renal diseases. This strategic pivot into rare and orphan diseases represents a significant long-term value driver, promising to diversify the company's revenue streams and reduce its reliance on the highly competitive cholesterol market. The J.P. Morgan conference provides the ideal platform to articulate this long-term vision, reassuring the market that Esperion is building a company designed for growth well into the next decade.